A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or With Severe Hypertriglyceridemia
Sponsor: Ionis Pharmaceuticals, Inc.
A PHASE3 clinical study on Atherosclerosis and Cardiovascular Diseases, this trial is completed. The trial is conducted by Ionis Pharmaceuticals, Inc. and has accumulated 22 data snapshots since 2022. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
22 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Jan 2025 — May 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 17 earlier versions
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2023 — Jun 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
First recorded
Nov 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ionis Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aarhus, Denmark , Amsterdam, Netherlands , Arnhem, Netherlands , Badalona, Spain , Baltimore, United States , Barcelona, Spain , Bardejov, Slovakia , Barrie, Canada , Beverly Hills, United States and 125 more locations